Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. develops clinical-stage protein kinase inhibitor therapeutics for cardiopulmonary disease, with IKT-001, an oral prodrug of imatinib mesylate, as its lead program for pulmonary arterial hypertension. Company news centers on the IMPROVE-PAH clinical program, FDA interactions, clinical-development milestones, and PAH biology involving Abelson tyrosine kinase, platelet-derived growth factor receptors and c-KIT.
Recurring updates also cover operating results, development spending, equity compensation under Nasdaq rules, common-stock and warrant financing activity, and leadership or commercial-planning changes tied to the PAH program.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.